KRAS mutant lung cancer: progress thus far on an elusive therapeutic target
AbstractThe KRAS mutation remains the most common driver mutation in patients with non‐small cell lung cancer (NSCLC) and confers a poor prognosis. Thus far, efforts to target this mutation over the last two decades have been unsuccessful. Over the past 5 years, many efforts to develop drugs that ta...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-12-01
|
| Series: | Clinical and Translational Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40169-015-0075-0 |